Invoicing Of Research & Development Costs (Iph5201) was Innate Pharma’s largest revenue line in fiscal 2025, bringing in $1.67M of $2.79M (60%).
| Types of contracts [axis] | FY 2017 | FY 2018 | FY 2019 | FY 2022 | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Collaboration & Licensing Agreements | — | — | — | — | |||
| Monalizumab Agreement | — | $22.38M | $9.50M | $220.00K | |||
| Agreement Related To Additional Preclinical Molecules With Astrazeneca | $20.00M | — | — | — | |||
| Of Which Preclinical Molecules Agreement - Astrazeneca | — | $17.40M | — | — | |||
| Of Which Sanofi Agreement 2022 - Anket Iph67 -Recognition Of License Initial Payment & Income Related To The Progress Of Related Research Program | — | — | $15.80M | — | |||
| 2015 Monalizumab Agreement, With Astrazeneca | $13.40M | — | — | — | |||
| Iph5201 Agreement, With Astrazeneca | — | $4.68M | — | — | |||
| Of Which Sanofi Agreement 2022 - Anket Iph62 - Recognition Of License Initial Payment & Income Related To The Completion Of Work In Line With The Joint Research Program | — | — | $18.87M | $400.00K | |||
| Invoicing Of Research & Development Costs (Iph5201 And Avdoralimab Agreements) | — | — | — | — | |||
| Of Which Takeda Agreement 2023 | — | — | $4.55M | — | |||
| Iph6101 Agreement, With Sanofi | — | $4.00M | $2.00M | — | |||
| Invoicing Of Research & Development Costs (Iph5201) | — | $1.39M | $1.17M | $1.67M | |||
| Of Which Other Agreements | — | $353.00K | — | — | |||
| Others | — | $10.00K | $11.00K | $501.00K | |||
| Other Agreement | — | — | — | — | |||
| Exchange Gains (Loss) On Collaboration Agreements | — | -$627.00K | — | — | |||
| Collaboration Agreement | — | — | — | — | |||
| Total | $33.40M | $49.58M | $51.90M | $2.79M |
Innate Pharma brought in $2.79M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Innate Pharma regrouped these revenue lines after fiscal 2023, so the total does not compare directly with that year's $51.90M. Invoicing Of Research & Development Costs (Iph5201) was the largest at $1.67M (59.8%), ahead of Others at $501.00K (18.0%) and Of Which Sanofi Agreement 2022 - Anket Iph62 - Recognition Of License Initial Payment & Income Related To The Completion Of Work In Line With The Joint Research Program at $400.00K (14.4%). The remaining revenue line, Monalizumab Agreement, brought in $220.00K.
Compared with fiscal 2023, the previous year with figures, Others grew fastest, up 4,454.5% to $501.00K, while Of Which Sanofi Agreement 2022 - Anket Iph62 - Recognition Of License Initial Payment & Income Related To The Completion Of Work In Line With The Joint Research Program fell the most, down 97.9% to $400.00K.
Innate Pharma began breaking out Of Which Sanofi Agreement 2022 - Anket Iph62 - Recognition Of License Initial Payment & Income Related To The Completion Of Work In Line With The Joint Research Program in fiscal 2023, when it brought in $18.87M. Innate Pharma stopped reporting Agreement Related To Additional Preclinical Molecules With Astrazeneca ($20.00M in fiscal 2022), Of Which Preclinical Molecules Agreement - Astrazeneca ($17.40M in fiscal 2022), Of Which Sanofi Agreement 2022 - Anket Iph67 -Recognition Of License Initial Payment & Income Related To The Progress Of Related Research Program ($15.80M in fiscal 2023) and five others as separate revenue lines.
Innate Pharma (IPHA) reports its revenue by types of contracts [axis]. In fiscal 2025, Invoicing Of Research & Development Costs (Iph5201) was its largest revenue line, bringing in $1.67M (59.8% of the total), followed by Others at $501.00K (18.0%).
Invoicing Of Research & Development Costs (Iph5201) was Innate Pharma's largest revenue line in fiscal 2025, bringing in $1.67M, or 59.8% of the $2.79M total across its four revenue lines.
Every figure comes from Innate Pharma's annual financial filings, as reported. Each line keeps the name Innate Pharma gives it, and years follow its fiscal calendar.
Innate Pharma's revenue by types of contracts [axis] goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.